📊 BOLD Key Takeaways
Is Boundless Bio, Inc. (BOLD) a Good Investment?
Boundless Bio is a pre-revenue biopharmaceutical company with strong balance sheet metrics but facing critical near-term cash constraints. With -15M quarterly operating cash flow against only 17.5M cash reserves, the company has approximately one quarter of runway before requiring additional financing. While zero debt and 86.4M in equity are positives, the combination of zero revenue, unsustainable cash burn, and inherent biotech development risk creates an unfavorable risk-reward profile for most investors.
Boundless Bio remains a pre-revenue biotech with deep operating losses and negative free cash flow, so the core fundamental story is still driven by capital consumption rather than business profitability. The balance sheet is relatively clean, with no long-term debt and strong reported liquidity, but the company’s cash burn and lack of commercial revenue keep execution risk high. Fundamental improvement will depend on materially narrowing losses and sustaining liquidity without heavy shareholder dilution.
Boundless Bio, Inc. Key Strengths (BOLD)
- Strong balance sheet with 86.4M stockholders' equity and zero long-term debt
- Excellent liquidity position (9.87x current ratio) eliminates near-term solvency risk
- Minimal capital expenditure (8K) indicates lean operations appropriate for early-stage biotech development
- Debt-free balance sheet reduces financial distress risk
- Very strong current and quick ratios indicate ample near-term liquidity
- Positive year-over-year EPS improvement suggests some operating cost discipline
BOLD Stock Risks: Boundless Bio, Inc. Investment Risks
- Critical cash runway: Only 17.5M cash against 15M quarterly operating burn (approximately one quarter of operations)
- Pre-revenue business model: Zero revenue; entire business thesis depends entirely on unproven pipeline execution
- High biotech development risk: Unfavorable clinical outcomes, regulatory setbacks, or failure to achieve milestones could be fatal
- No reported revenue means the business model is not yet self-funding
- Large operating and free cash flow losses indicate continued cash burn
- High likelihood of future external financing or dilution if losses persist
Key Metrics to Watch
- Quarterly cash burn rate and runway remaining before next financing need
- Clinical trial progress, patient enrollment, and regulatory milestone announcements
- Capital raise announcements and terms of financing to determine dilution impact
- Quarterly operating cash burn and total liquidity runway
- Any emergence of sustainable revenue or major reduction in operating losses
Boundless Bio, Inc. (BOLD) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.87x current ratio provides a solid financial cushion.
BOLD Profit Margin, ROE & Profitability Analysis
BOLD vs Healthcare Sector: How Boundless Bio, Inc. Compares
How Boundless Bio, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Boundless Bio, Inc. Stock Overvalued? BOLD Valuation Analysis 2026
Based on fundamental analysis, Boundless Bio, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Boundless Bio, Inc. Balance Sheet: BOLD Debt, Cash & Liquidity
BOLD Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Boundless Bio, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-3.85 indicates the company is currently unprofitable.
BOLD Revenue Growth, EPS Growth & YoY Performance
Boundless Bio, Inc. Dividends, Buybacks & Capital Allocation
BOLD SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Boundless Bio, Inc. (CIK: 0001782303)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BOLD
What is the AI rating for BOLD?
Boundless Bio, Inc. (BOLD) has a Combined AI Grade of C from Claude (C) and ChatGPT (C) with 79% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are BOLD's key strengths?
Claude: Strong balance sheet with 86.4M stockholders' equity and zero long-term debt. Excellent liquidity position (9.87x current ratio) eliminates near-term solvency risk. ChatGPT: Debt-free balance sheet reduces financial distress risk. Very strong current and quick ratios indicate ample near-term liquidity.
What are the risks of investing in BOLD?
Claude: Critical cash runway: Only 17.5M cash against 15M quarterly operating burn (approximately one quarter of operations). Pre-revenue business model: Zero revenue; entire business thesis depends entirely on unproven pipeline execution. ChatGPT: No reported revenue means the business model is not yet self-funding. Large operating and free cash flow losses indicate continued cash burn.
What is BOLD's revenue and growth?
Boundless Bio, Inc. reported revenue of N/A.
Does BOLD pay dividends?
Boundless Bio, Inc. does not currently pay dividends.
Where can I find BOLD SEC filings?
Official SEC filings for Boundless Bio, Inc. (CIK: 0001782303) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BOLD's EPS?
Boundless Bio, Inc. has a diluted EPS of $-0.60.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is BOLD's fundamental grade?
Based on our AI fundamental analysis in June 2026, Boundless Bio, Inc. has a C grade with 79% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is BOLD stock overvalued or undervalued?
Valuation metrics for BOLD: ROE of -15.7% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is BOLD's AI grade for 2026?
Our dual AI analysis gives Boundless Bio, Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is BOLD's free cash flow?
Boundless Bio, Inc.'s operating cash flow is $-15.0M, with capital expenditures of $8.0K.
How does BOLD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -15.7% (avg: 15%), current ratio 9.87 (avg: 2).